Sakar Healthcare Limited Stock Price Today (NSE: SAKAR)
Fundamental Score
Sakar Healthcare Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sakar Healthcare Limited share price today is ₹1105.40, down 2.83% on NSE/BSE as of 16 September 2026. Sakar Healthcare Limited (SAKAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.46K (Cr). The 52-week high for SAKAR share price is ₹1211.00 and the 52-week low is ₹330.00. At a P/E ratio of 68.23x, SAKAR is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 10.00% and a debt-to-equity ratio of 0.17.
Sakar Healthcare Limited Share Price Chart — NSE/BSE Historical Performance
Sakar Healthcare Limited share price chart: 27.36% return over the past month. 52-week high ₹1211.00, 52-week low ₹330.00.
Sakar Healthcare Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1137.00 | ₹1143.90 | ₹1042.70 | ₹1105.40 | 1.64L (Cr) | |
| ₹1178.00 | ₹1179.00 | ₹1117.10 | ₹1137.55 | 1.19L (Cr) | |
| ₹1118.00 | ₹1195.00 | ₹1096.05 | ₹1158.55 | 1.81L (Cr) | |
| ₹1149.00 | ₹1165.90 | ₹1084.00 | ₹1117.30 | 91.28K (Cr) | |
| ₹1169.00 | ₹1178.95 | ₹1114.00 | ₹1152.35 | 1.42L (Cr) | |
| ₹1140.00 | ₹1211.00 | ₹1112.05 | ₹1157.85 | 5.80L (Cr) | |
| ₹1021.00 | ₹1124.00 | ₹1018.95 | ₹1109.20 | 3.40L (Cr) | |
| ₹1012.00 | ₹1019.00 | ₹987.95 | ₹1013.90 | 87.98K (Cr) | |
| ₹1000.00 | ₹1017.00 | ₹960.05 | ₹1006.95 | 1.68L (Cr) | |
| ₹993.00 | ₹1024.00 | ₹975.50 | ₹985.80 | 3.86L (Cr) |
Sakar Healthcare Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹866.30 | ₹1211.00 | ₹864.00 | ₹1105.40 | +27.60% | |
| ₹908.70 | ₹980.00 | ₹831.55 | ₹863.35 | -4.99% | |
| ₹840.50 | ₹960.00 | ₹794.00 | ₹885.25 | +5.32% | |
| ₹818.00 | ₹889.95 | ₹755.00 | ₹838.10 | +2.46% | |
| ₹628.05 | ₹837.75 | ₹520.00 | ₹796.50 | +26.82% | |
| ₹528.50 | ₹661.95 | ₹492.20 | ₹628.05 | +18.84% | |
| ₹481.00 | ₹577.95 | ₹465.00 | ₹498.45 | +3.63% | |
| ₹377.00 | ₹569.95 | ₹377.00 | ₹494.60 | +31.19% | |
| ₹409.70 | ₹439.00 | ₹361.00 | ₹391.10 | -4.54% | |
| ₹377.00 | ₹444.30 | ₹352.50 | ₹409.20 | +8.54% | |
| ₹363.80 | ₹411.80 | ₹356.25 | ₹375.45 | +3.20% | |
| ₹355.00 | ₹394.95 | ₹345.50 | ₹361.20 | +1.75% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sakar Healthcare Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sakar Healthcare Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SAKAR across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Operating Margins (26.96%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (120.17%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (38.37%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (21.59% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (23.33% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (6.06x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (52.86%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (10.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 68.23x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (7.58x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Negative Free Cash Flow (₹-43.84 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sakar Healthcare Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sakar Healthcare Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
63.5/100 | ₹1105.40₹1105 | ₹2459.50₹2459.50 | 68.23Average 68.2 Average | 10.00%Poor 10.00% Poor | 13.16%Average 13.16% Average | 0.17Excellent 0.2 Excellent | 23.33%Excellent 23.33% Excellent | 21.59%Excellent 21.59% Excellent | 0.00% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Sakar Healthcare Limited PE Ratio History
Historical price-to-earnings ratio for SAKAR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹5.63 | ₹296.45 | 52.7x |
| FY 2023 | ₹6.86 | ₹400.05 | 58.3x |
| FY 2022 | ₹10.09 | ₹224.25 | 22.2x |
| FY 2021 | ₹708.58 | ₹162.65 | 0.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sakar Healthcare Limited Quarterly Performance
Latest quarterly metrics for SAKAR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
38.37%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
120.17%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
21.59%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
23.33%
Compounded annual net profit growth over 5 years
Sakar Healthcare Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SAKAR — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Sakar Healthcare Limited Financial Statements
Annual income statement, balance sheet and cash flow for Sakar Healthcare Limited (SAKAR) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Sakar Healthcare Limited
About SAKAR (Sakar Healthcare Limited)
Sakar Healthcare Ltd is a dynamic pharmaceutical company committed to innovation and quality in healthcare solutions. Focused on both domestic and international markets, Sakar Heal...thcare meticulously crafts and distributes a diverse range of pharmaceutical formulations. Their expertise lies in the production of various dosage forms, including complex sterile injectables, meticulously crafted oral solids, and palatable liquid formulations. Through advanced manufacturing processes and stringent quality control measures, Sakar Healthcare ensures that each product adheres to the highest industry standards. The company consistently strives to meet the evolving healthcare needs of patients worldwide by delivering safe, effective, and affordable medicines. Sakar Healthcare demonstrates a dedication to developing cutting-edge pharmaceutical products and processes. With a team of skilled scientists and researchers, the company invests significant resources in research and development to create innovative solutions. This commitment extends to improving existing formulations and exploring new therapeutic avenues. Sakar Healthcare emphasizes compliance with regulatory guidelines and global best practices in pharmaceutical manufacturing. This commitment underscores their ambition to be a trusted partner in healthcare, providing reliable and high-quality products to enhance patient outcomes and overall well-being. Sakar Healthcare's comprehensive product portfolio spans a wide spectrum of therapeutic areas, addressing critical healthcare needs across diverse patient populations. From addressing common infections with anti-infectives to managing pain with analgesics, the company offers a range of essential medications. Furthermore, they cater to specialized treatment areas, including antihistamines for allergies, anthelmintics for parasitic infections, and anti-malarials for malaria. Sakar Healthcare aims to provide affordable access to essential medicines to improve lives and promote better health outcomes across the globe. They continuously adapt their product offerings to meet the changing needs of the healthcare landscape.
Company Details
Key Leadership
SAKAR Share Price: Frequently Asked Questions
What is the current share price of Sakar Healthcare Limited?
Sakar Healthcare Limited (SAKAR) trades at ₹1105.40 on NSE. Market cap ₹2.46K (Cr). Educational data only.
What is the P/E ratio of Sakar Healthcare Limited?
Sakar Healthcare Limited has a P/E of 68.23x vs industry average 34.89x.
What is the Bull Run score for Sakar Healthcare Limited?
Sakar Healthcare Limited has a Bull Run score of 63.5/100 based on 25+ financial parameters.
Does Sakar Healthcare Limited pay dividends?
Sakar Healthcare Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Sakar Healthcare Limited?
Sakar Healthcare Limited has ROE of 10.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sakar Healthcare Limited?
Sakar Healthcare Limited has debt-to-equity of 0.17.
Is Sakar Healthcare Limited a good investment?
Bull Run gives Sakar Healthcare Limited a score of 63.5/100. This is not investment advice — consult a SEBI-registered advisor.